Evidence Tier: Tier 1 (Strong)
Calcium supplementation demonstrates consistent benefits for slowing bone loss and increasing bone mineral density in postmenopausal women and elderly populations.
In a 4-year randomized controlled trial with 84 participants, those consuming 1,988 mg of calcium daily showed no bone loss at the hip and ankle, while the control group (952 mg/day) lost significantly more bone at all hip and ankle sites. This protective effect is particularly pronounced when calcium is combined with vitamin D.
A 3-year trial in 593 participants found that 800 IU vitamin D combined with 1,000 mg calcium increased total body bone mineral density (BMD) by 0.84%, compared to 0.19% in the control group (p=0.011). However, changes at the lumbar spine and femoral neck were nonsignificant, suggesting site-specific effects.
In adolescents, the benefits appear even stronger. Adolescent males receiving 230 mg/day to 500 mg/day of additional calcium supplementation over 24 months showed significantly greater lean body mass (48.8-49.1 kg) compared to the low-dose group (46.7 kg, p<0.05). Notably, this effect was not observed in females.
Evidence Tier: Tier 2 (Weak)
Calcium supplementation shows no consistent benefit for fat loss in most populations. While some studies suggest small effects in specific subgroups—children, adolescents, and premenopausal women—the largest and most rigorous trials in overweight and obese adults found no meaningful weight or fat reduction.
A 2016 meta-analysis of 33 randomized controlled trials involving 4,733 participants showed no significant weight change overall (mean -0.01 kg; 95% CI -0.02 to 0.00 kg; p=0.12) in adults. However, a small effect was detected in children and adolescents (-0.26 kg, p<0.001), suggesting age-dependent responses.
More recent analysis, including a 2024 Cochrane meta-analysis on calcium supplementation in overweight and obese individuals, found inconsistent efficacy with limited clinical benefit. This means calcium supplementation cannot be reliably recommended as a weight loss tool for adults.
Evidence Tier: Tier 2 (Weak)
Calcium supplementation shows promise for lean body mass gains in adolescents but lacks robust evidence for direct muscle growth in adults. Most human studies focus on bone health rather than muscle hypertrophy per se.
As noted above, adolescent males receiving higher calcium doses showed greater lean body mass gains—approximately 2.4 kg more than the low-dose group over 24 months. In contrast, older women (n=1,368, mean age 75.2 years) receiving 1.2 g/day for one year showed no differences in body mass index, lean body mass, or fat mass compared to placebo.
This suggests that while calcium may support musculoskeletal development during growth phases, it does not consistently promote muscle growth in adults.
Evidence Tier: Tier 3 (Mixed/Limited)
Calcium supplementation shows moderate evidence for supporting bone health and reducing bone resorption markers during pregnancy, lactation, and in postmenopausal women, but evidence specifically for acute injury recovery is limited and mixed.
In pregnant women (n=31, crossover RCT), 1,200 mg calcium supplementation reduced the urinary NTX bone resorption marker by 13.6% (96.8 vs. 83.2 nM BCE/mM creatinine, p<0.001). This indicates that calcium supplementation slows the rate at which pregnant women lose bone—an important clinical consideration given the calcium demands of pregnancy.
In adolescent girls (n=96, 18-month RCT), an additional 792 mg/day calcium supplementation showed significantly greater bone mineral content gains across all skeletal sites and lower bone resorption markers at 18 months (p<0.05). However, differences were not evident at the 42-month follow-up, suggesting that benefits may be temporary rather than sustained.
Evidence Tier: Tier 3 (Mixed/Limited)
Calcium supplementation shows modest benefits for bone health in postmenopausal women and elderly populations, with consistent effects on slowing bone loss at specific sites. However, efficacy for fracture prevention remains unproven, with most studies showing statistically nonsignificant reductions in fracture risk.
The 4-year study mentioned above demonstrated clear benefits for preventing bone loss at the hip and ankle, but whether this translates to fewer actual fractures remains uncertain from the current evidence base.
Evidence Tier: Tier 3 (Mixed/Limited)
Calcium supplementation shows probable efficacy for reducing inflammation in specific clinical contexts, particularly preeclampsia prevention and postpartum immune function, but evidence is mixed and mostly limited to small RCTs with inconsistent effect sizes.
In a meta-analysis of 7 RCTs, calcium combined with low-dose aspirin reduced preeclampsia incidence to an odds ratio of 0.20 (95% CI 0.10-0.37) and gestational hypertension to OR 0.15 (95% CI 0.07-0.31). These are dramatic protective effects, though specific to pregnancy complications.
In 101 pregnant women at preeclampsia risk, 1,500 mg/day calcium significantly decreased inflammatory cytokines IL-2, IL-6, IL-4, and interferon-γ (p<0.005) and increased antioxidant markers like vitamin C, suggesting meaningful immune modulation in this population.
Evidence Tier: Tier 1 (No Benefit)
Calcium supplementation has not been shown to improve cognition in any human study. The limited evidence suggests no benefit for cognitive function in cognitively normal or impaired populations.
In a 12-month RCT involving 60 men with prostate cancer on androgen deprivation therapy, multicomponent exercise plus 1,200 mg/day calcium supplementation had no effect on cognition as measured by CogState, Trail-making test, Rey auditory-verbal learning test, and Digit span (p>0.05 for all measures).
Hypoparathyroid patients treated with calcium supplementation and vitamin D analogs still showed reduced quality of life and cognitive impairment compared to healthy controls, despite normalized serum calcium levels.
Evidence Tier: Tier 2 (Weak)
Calcium supplementation shows modest improvements in sleep quality in specific populations—particularly premenopausal women, menopausal women, and those with low vitamin D status—but evidence is limited to small human studies. No large-scale RCTs demonstrate consistent, clinically meaningful sleep improvements across general populations.
In 51 premenopausal women with prediabetes, 500 mg/day calcium supplementation for 24 weeks improved sleep quality on the Pittsburgh Sleep Quality Index (PSQI), with particularly strong effects in women with low baseline vitamin D (<30 ng/mL) and menopausal individuals (p<0.05). Interestingly, improvements in sleep efficiency showed a negative correlation with insulin efficiency (r=-0.264, p=0.007), suggesting a trade-off between metabolic and sleep benefits.
Evidence Tier: Tier 2 (Weak)
Calcium intake is associated with reduced fall risk and improved bone health markers in observational studies, but evidence for longevity benefit remains limited. Meta-analyses show no meaningful effect on all-cause mortality.
Dietary calcium intake was associated with a 20% lower fall risk comparing the lowest versus highest quartile in a longitudinal analysis of 24,066 community-dwelling adults over 5 years (adjusted OR 1.20). Falls are a major cause of morbidity and mortality in older adults, so this effect is clinically relevant.
In the EPIC-Norfolk prospective cohort (n=17,968, 20-year follow-up), mid-range calcium intake of 771-926 mg/day was associated with reduced all-cause mortality (HR 0.91, 95% CI 0.83-0.99), as was 1,074-1,254 mg/day (HR 0.85, 95% CI 0.77-0.93) compared to the lowest quintile (<770 mg/day). However, the highest calcium intake groups showed no further mortality benefit, suggesting a U-shaped or plateau relationship.
Evidence Tier: Tier 2 (Weak)
Calcium supplementation shows plausible immune-modulatory effects in limited human studies, but efficacy for preventing infections or improving immune function remains unproven. The inflammatory cytokine data mentioned in the anti-inflammation section is relevant here.
In schoolchildren (n=135, RCT), vitamin D and calcium supplementation (1,000 IU D3 + 500 mg calcium) increased serum 25(OH)D by 34% but showed no greater improvement in infection rates versus placebo. Improvements in respiratory tract infections and total infections were similar across all three groups, suggesting that immune benefits are not straightforward.
Evidence Tier: Tier 1 (No Benefit)
Calcium supplementation does not improve energy levels or physical performance in humans. Available evidence focuses on bone health, metabolic markers, and disease management, with no studies demonstrating enhanced energy or fatigue reduction as a primary outcome.
In 13 physically active males, high-calcium supplementation (1,400 mg/day for 14 days) did not alter lipid or carbohydrate utilization rates during exercise compared to control (400 mg/day). Maximum lipid utilization rates showed no significant differences (p>0.05).
Similarly, in 15 overweight women, 1,500 mg/day for 3 months did not alter body weight, lipid oxidation, lipolysis, or appetite sensations despite increased urinary calcium excretion.
Evidence Tier: Tier 1 (No Benefit)
Calcium supplementation has no demonstrated efficacy for skin or hair health. Retrieved studies focus on bone metabolism, cancer prevention, and mineral homeostasis—not skin or hair outcomes.
In a randomized trial (n=2,259, median 8-year follow-up), 1,200 mg/day calcium supplementation was unrelated to basal cell carcinoma incidence (HR 1.01, 95% CI 0.74-1.39). Another large RCT (n=2,303 postmenopausal women, 4 years) found no meaningful difference in skin cancer outcomes with calcium and vitamin D3 supplementation (1,500 mg + 2,000 IU daily) compared to placebo.
Evidence Tier: Tier 2 (Mixed)
Calcium supplementation shows mixed evidence for gut health. Some studies demonstrate mechanisms involving gut microbiota modulation, but human evidence is limited to observational studies with small samples. Large meta-analyses show calcium supplementation causes gastrointestinal adverse events rather than improving gut health.
Meta-analysis of 19 RCTs (69,234 patients) found that calcium with vitamin D supplementation significantly increased gastrointestinal adverse reactions compared to control. In contrast, in an animal model of type 2 diabetic osteoporosis, calcium carbonate combined with senolytics increased short-chain fatty acid-producing bacteria (Lachnospiraceae, Bacteroides) and decreased inflammatory bacteria (Mucispirillum), with corresponding beneficial metabolite changes.
Evidence Tier: Tier 2 (No Benefit; Possible Harm)
Calcium supplementation does not improve heart health in general populations. RCT evidence suggests it may slightly increase cardiovascular risk (10-20% higher myocardial infarction risk), while dietary calcium shows no such association. Efficacy for heart health is not proven.
Meta-analysis of 12 RCTs found calcium supplements NOT associated with reduced myocardial infarction, stroke, or cardiovascular mortality. More concerning, pooled analysis of RCTs showed calcium supplements increased coronary heart disease risk by 8% (RR 1.08, 95% CI 1.02-1.22) and by 20% when used alone (RR 1.20, 95% CI 1.08-1.33). This suggests that while dietary calcium is safe, supplemental calcium—particularly when taken without food—may carry a small cardiovascular risk.
Evidence Tier: Tier 1 (No Benefit)
Calcium supplementation has no proven efficacy for improving liver health. Calcium supplementation actually increased serum cholesterol in postmenopausal women via reduced hepatic cholesterol catabolism mediated by elevated intracellular liver calcium—a potentially adverse effect.
Evidence Tier: Tier 3 (Proven for Hypoparathyroidism)
Calcium supplementation is proven effective for treating hypoparathyroidism-induced hypocalcemia. Standard first-line therapy combining calcium supplementation and vitamin D effectively normalizes serum calcium levels in hypoparathyroid patients.
In 5,671 thyroidectomy patients, the need for intravenous calcium supplementation and its duration predicted permanent hypoparathyroidism development, underscoring calcium's essential role in managing post-surgical complications.
Evidence Tier: Tier 2 (Limited Promise)
Calcium supplementation shows promise for improving female fertility in obesity-related subfertility and may support semen quality in vitamin D-deficient men, but human evidence is limited to small studies and observational data.
In high-fat diet-fed female mice, calcium supplementation alleviated estrous cycle irregularity and subfertility, with shorter conception time, higher fertility index, and more implantations. In infertile males with oligoasthenozoospermia, vitamin D plus calcium supplementation produced significant improvements in mean sperm concentration and progressive sperm motility after 6 months (p<0.001), with a clinical pregnancy rate of 8.33%.
Evidence Tier: Tier 3 (Indirect Benefits)
Calcium supplementation combined with exercise shows consistent benefits for bone mineral density gains in children and adolescents, with modest effects in postmenopausal women. However, evidence for direct athletic performance improvement is limited.
Exercise plus calcium produced 2% greater femur bone mineral content (BMC) and 3% greater tibia-fibula BMC increases versus placebo alone in prepubertal boys. In postmenopausal women, 800 mg daily calcium combined with weight-bearing exercise increased femoral neck, trochanteric, and lumbar spine BMD by 1-2% over 12 months.
The standard recommendation for calcium supplementation is 500-600 mg elemental calcium per dose, taken twice daily, for a total daily intake of 1,000-1,200 mg. This matches the Recommended Dietary Allowance (RDA) for most adults.
When taking calcium supplements:
- Spacing: Divide doses into 500-600 mg portions to optimize